When was Genmab founded?

Genmab was founded in 1999 and raised its 1st funding round 10 years after it was founded.

Where is Genmab located?

Genmab is headquartered in Copenhagen, Denmark. It is registered at Princeton, New Jersey.

Who is the current CEO of Genmab?

Jan van de Winkel of Genmab. They have also founded 1 company.

How many employees does Genmab have?

As of Jan 02, 2026, the latest employee count at Genmab is 2705.

Is Genmab a funded company?

Genmab is a funded company, having raised an undisclosed amount across 3 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Oct 01, 2009.

When was the latest funding round of Genmab?

Genmab's latest funding was a $***** Post IPO round on Jan 23, 2014, with participation from 0 investor.

Where does Genmab rank among its competitors?

Genmab ranks 109th amongst 3237 active competitors, of which 1108 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Moderna, which secured $590M in Jan, 2025.

Who are the top competitors of Genmab?

Genmab's top competitors include Jazz Pharmaceuticals, Moderna and Sana Biotechnology. Among them, Moderna secured the most recent funding round in January, 2025.

Genmab - 2026 Company Profile, Team, Funding, Competitors & Financials

Genmab is a public company based in Copenhagen (Denmark), founded in 1999 by Jan van de Winkel. It operates as a Developer of antibody therapeutics for the treatment of cancer and autoimmune diseases. Genmab has raised an undisclosed amount in funding. The company has 3237 active competitors, including 1108 funded and 770 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Moderna and Sana Biotechnology.

Company Details

Developer of antibody therapeutics for the treatment of cancer and autoimmune diseases. The company uses proprietary DuoBody, HexaBody, DuoHexaBody, and HexElect technologies, to harness the power of human antibodies to develop a robust pipeline of products such as Teprotumumab for thyroid eye disease, Tisotumab vedotin for solid and cervical cancer, Darzalex for multiple myeloma, and more.

Website: www.genmab.com/
Registered Address: Princeton, New Jersey

Key Metrics

Founded Year

1999

Location

Copenhagen, Denmark

Stage

Public

Latest Funding Round

Post IPO, Jan 23, 2014, $*****

Investors

HBM Healthcare Investments & 3 more

Ranked

109^th among 3237 active competitors

Employee Count

2,705 as on Jan 02, 2026

Investment & Acquisitions

Merus & 2 more

Similar Companies

Jazz Pharmaceuticals & 3028 more

Exit Details

Public

View Genmab's full profile

Genmab is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Genmab A/s CIN: 21023884 , Denmark, Active	Jun 10, 1998	-	567 (As on Mar 31, 2024)
GENMAB US, INC. CIN: 262011084 , United States, Active	Dec 26, 999	-	1067 (As on Dec 31, 2024)	-

Genmab got listed on Oct 20, 2000.

Click here to take a look at Genmab's IPO in detail

Genmab has raised funding over 3 rounds. Its first funding round was on Oct 01, 2009. Genmab has 4 institutional investors.

Here is the list of recent funding rounds of Genmab:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 23, 2014	4281241	Post IPO	6326438	8843749	7651591	6068760
Jul 01, 2010	5307292	Post IPO	3653257	8997650	3896934	4306354
Oct 01, 2009	2431581	Post IPO	2406716	3781099	6012688	GSK

Access funding benchmarks and valuations. Sign up today!

View details of Genmab's funding rounds and investors

The founders of Genmab is Jan van de Winkel. Jan van de Winkel is the CEO of Genmab.

Here are the details of Genmab's key team members:

Jan van de Winkel: Co-Founder & CEO of Genmab and founder of 1 other company.

View details of Genmab's Founder profiles and Board Members

Genmab's employee count trend

Genmab has 2,705 employees as of Jan 26. Here is Genmab's employee count trend over the years:

Uncover Genmab's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Genmab include Jazz Pharmaceuticals, Moderna and Sana Biotechnology. Here is the list of Top 10 competitors of Genmab, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, Astrazeneca & 31 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
4th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	BB Biotech, RA Capital Management & 14 others	74/100
5th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
6th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	73/100
7th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
8th	Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public	Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others	-	BB Biotech, Kaccelerator & 7 others	72/100
9th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	72/100
10th	MacroGenics 2000, Rockville (United States), Public	Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease	$126M	Nextech Venture, Ventures West & 29 others	72/100
109th	Genmab 1999, Copenhagen (Denmark), Public	Developer of antibody therapeutics for the treatment of cancer and autoimmune diseases	-	HBM Healthcare Investments, NB Capital & 2 others	58/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Genmab's competitors? Click here to see the top ones

Genmab has made 1 investment in Paradigm Therapeutics and acquired Merus and Profound Bio.

Here is the list of these investments and acquisitions:

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Dec 12, 2025	Acquisition	Merus	2003	Utrecht (Netherlands)
Apr 03, 2024	Acquisition	Profound Bio	2018	Woodinville (United States)
Dec 09, 2002	Investments	Paradigm Therapeutics	1999	Cambridge (United Kingdom)